Shots:
- The US FDA has approved BESREMi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), expanding BESREMi product label beyond polycythemia vera
- Approval was supported by durable ELN responses and hematologic control in adults with ET. In P-III (SURPASS-ET) trial, it outperformed anagrelide in durable response rates & reduced thromboembolic events over 12mos.
- BESREMi is a long-acting interferon therapy for ET that uses monopegylation & an extended half-life to target disease-driving bone marrow cells, reduce elevated platelet counts and lower disease burden
Ref: Businesswire | Image: PharmaEssentia | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
